{"entity":{"id":"cinnagen","kind":"company","name":"CinnaGen","aka":["CinnaGen Co.","Cinnagen","سیناژن","CinnaGen Pharmaceutical Group"],"tldr":"An Iranian maker of biological medicines, including copies of cancer antibodies, whose own pertuzumab copy matched the original in a phase 3 breast cancer trial.","summary":"CinnaGen describes itself as a biopharmaceutical company with a head office in Shahrak-e Gharb, Tehran, and a manufacturing site in the Simin Dasht industrial area of Karaj, with product lines including oncology and haematology and pages on biosimilars and clinical trials. Its site, read from an Internet Archive copy of 30 September 2026, lists AryoGen among its family of companies.\n\nIt sponsored the phase 3 equivalence trial of P013, its proposed pertuzumab biosimilar (NCT04957212, also registered in the Iranian Registry of Clinical Trials as IRCT20150303021315N11), in which 214 women with HER2-positive breast cancer were randomised to P013 or the originator Perjeta with trastuzumab, carboplatin and docetaxel before surgery; breast pathological complete response was 67.62% against 71.57%, within the equivalence margin. cinnagen.com did not answer from here on 4 November 2026.","asOf":"2026-11-04","links":[{"label":"CinnaGen: about us (Internet Archive copy of 30 September 2026)","url":"https://web.archive.org/web/20260930035205/https://www.cinnagen.com/about-us/"},{"label":"ClinicalTrials.gov NCT04957212","url":"https://clinicaltrials.gov/study/NCT04957212"},{"label":"Allahyari et al., P013 pertuzumab biosimilar (BMC Cancer 2022)","url":"https://doi.org/10.1186/s12885-022-09895-5"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["biosimilar-manufacturing"],"targets":[],"drugs":["pertuzumab"],"companies":["aryogen-pharmed"],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":["nct04957212"],"people":[],"bottlenecks":[],"keyPapers":["paper-p013-pertuzumab-biosimilar-bmc-cancer-2022"],"journals":[],"dependsOn":[],"notes":[],"hq":"Tehran","country":"IR","companyType":"biotech","website":"https://www.cinnagen.com","investors":[],"funding":[]},"route":"/companies/cinnagen/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"}],"company":[{"id":"aryogen-pharmed","kind":"company","name":"AryoGen Pharmed","route":"/companies/aryogen-pharmed/"}],"term":[{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/"}],"trial":[{"id":"nct04957212","kind":"trial","name":"P013 (CinnaGen pertuzumab) against Perjeta before surgery for HER2-positive breast cancer","route":"/trials/nct04957212/"}],"paper":[{"id":"paper-p013-pertuzumab-biosimilar-bmc-cancer-2022","kind":"paper","name":"Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial","route":"/key-papers/paper-p013-pertuzumab-biosimilar-bmc-cancer-2022/"}],"institution":[{"id":"iran-fda","kind":"institution","name":"Iran Food and Drug Administration (IFDA)","route":"/institutions/iran-fda/"}]}}